Biologics Outsourcing Global Market Report 2024

The biologics outsourcing market size has grown rapidly in recent years. It will grow from $17.74 billion in 2023 to $20.33 billion in 2024 at a compound annual growth rate (CAGR) of 14.6%. The growth observed in the historical period can be attributed to the increase in research and development (R&D) costs, regulatory pressure, a demand for specialized expertise, and globalization.

The biologics outsourcing market size is expected to see rapid growth in the next few years. It will grow to $33.29 billion in 2028 at a compound annual growth rate (CAGR) of 13.1%. The anticipated growth in the forecast period can be attributed to the growth of emerging markets, the rise of personalized medicine, strategic alliances, and the expiration of patents for biological drugs. Notable trends expected in the forecast period include advancements in technology, increased complexity in outsourcing, the expansion of the biosimilars market, integration of data analytics, and a focus on enhancing supply chain resilience.

The biologics outsourcing market is poised for growth, driven by the increasing number of cancer cases. Cancer, a diverse group of illnesses characterized by uncontrolled cell growth, demands specialized expertise and resources for developing biologic therapies such as monoclonal antibodies and immunotherapies. Biologics outsourcing is integral in providing the necessary infrastructure for the development, manufacturing, and clinical supply of these therapies, crucial for diagnosing and treating various cancer types. For instance, the National Center for Biotechnology Information reported 1,958,310 new cancer cases in the United States in January 2023, with a projected 609,820 cancer-related deaths. The prevalence of cancer is expected to escalate to 29.5 million new cases and 16.4 million deaths by 2040, emphasizing the role of biologics outsourcing in addressing the growing challenges posed by cancer.

The biologics outsourcing market is anticipated to be supported by the rise in chronic diseases and disabilities. Chronic conditions necessitate ongoing medical attention, and biologics prove effective in managing such complex health issues. Pharmaceutical and biotechnology companies are increasingly turning to outsourcing for specialized expertise in developing targeted treatments. The National Library of Medicine estimates a 99.5% increase in people aged 50 and older with at least one chronic illness, reaching 142.66 million in 2050. Additionally, the number of individuals with multimorbidity is projected to rise by 91.16% to 14.968 million in 2050. This surge in chronic diseases underscores the significance of biologics outsourcing in meeting the demands of intricate medical conditions.

A notable trend in the biologics outsourcing market is the emphasis on developments in biologics. Major companies are leveraging new technologies to sustain their market positions. For instance, Abzena, Alira Health, and Oncodesign launched DRIVE-Biologics, a consortium dedicated to biologic drug discovery and development programs. This collaborative effort streamlines information sharing and program deliverables, minimizing risks associated with biologics development. The partnership covers all stages, from biological discovery to clinical and commercial manufacturing, reflecting the commitment to advancing the field of biologics.

Companies in the biologics outsourcing market are focusing on establishing new Contract Development and Manufacturing Organizations (CDMOs) to maintain their market presence. Tanvex BioPharma USA Inc. introduced Tanvex CDMO in October 2023, offering end-to-end services for the development and manufacturing of biologics. Located in San Diego's biotech hub, Tanvex CDMO features state-of-the-art facilities, including R&D centers, GMP manufacturing suites, QC laboratories, and a GMP warehouse. With a proven track record, Tanvex CDMO aims to support early-stage companies in advancing biologics from conceptualization to commercialization.

In June 2022, Asahi Kasei Medical acquired Bionova Scientific LLC, expanding its bioprocess business to include biopharmaceutical contract development and manufacturing. Bionova Scientific LLC, a biologics CDMO, enhances Asahi Kasei Medical's capabilities in biologic drug development, manufacturing, and supply chain management, contributing to the broader landscape of biologics outsourcing.

Major companies operating in the biologics outsourcing market report are AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim GmbH, Lonza Group Ag, Catalent Inc., Sartorius Stedim Biotech S.A., Charles River Laboratories International Inc., WuXi Biologics Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., CordenPharma GmbH, Ajinomoto Bio-Pharma Services, Syngene International Limited, Rentschler Biopharma SE, Albany Molecular Research Inc., KBI Biopharma Inc., Fujifilm Diosynth Biotechnologies Inc., Avid Bioservices Inc., BioVectra Inc., ProBioGen AG, ABL Inc., Vibalogics GmbH, JHL Biotech Inc., Goodwin Biotechnology Inc., Crown Bioscience Inc., Cytovance Biologics Inc., LakePharma Inc., AGC Biologics GmbH, Biomay AG, Polpharma Biologics S.A.

North America was the largest region in the biologics outsourcing market in 2023. The regions covered in the biologics outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biologics outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary product types associated with biologics outsourcing include antibodies, recombinants, vaccines, proteins, and others. Antibodies are immune system-produced defense proteins, also known as antigens, formed in response to the presence of foreign material. These biologics can be derived from human, microbial, and other sources and find applications in areas such as oncology, cellular and gene therapy, blood and blood-related product development, vaccine development, stem cell research, among others. Biologics outsourcing is utilized by diverse end users, including pharmaceutical industries, biotechnology industries, and contract development and manufacturing organizations (CDMO).

The biologics outsourcing market research report is one of a series of new reports that provides biologics outsourcing market statistics, including the biologics outsourcing industry's global market size, regional shares, competitors with a biologics outsourcing market share, detailed biologics outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the biologics outsourcing industry. This biologics outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biologics outsourcing market includes revenues earned by entities through cell line development, contract research services, and optimization. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.